Company Overview
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
Recent News
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
Stock Overview
03/24/2023 04:00 PM EDT
Investor Relations
LHA Investor Relations
Tirth T. Patel
Vice President
T: 212.201.6614
tpatel@lhai.com